No Data
No Data
No Data
No Data
No Data
Market Mover | Lilly Shares Rise 7%, Q1 2024 Financial Results Beat, and Raises Full-year Revenue Guidance
The company raises its full-year revenue guidance by $2 billion to the range of $42.4 billion to $43.6 billion.
moomoo NewsApr 30 10:07 ET · Movers
Eli Lilly Reports $2 Billion From Mounjaro, Zepbound in Q1 2024
Yahoo Finance1minutes ago
Express News | Eli Lilly Says Proposed U.S. BIOSECURE Act Would Affect Pharmaceutical Supply Chain Elements; Currently Do Not See It To Have Material Impact On Business
Benzinga12:14 ET
Express News | Eli Lilly:Proposed US Biosecure Act Would Affect Pharmaceutical Supply Chain Elements;Currently Do Not See It to Have Material Impact on Business
Reuters12:12 ET
Top Midday Stories: Shares of Eli Lilly, HSBC Get Post-Earnings Bump; BBVA Exploring Merger With Sabadell; FTC Disputes 300 'Junk' Patent Listings
All three major Wall Street indexes were down in late-morning trading Tuesday in the wake of higher-than-expected employment cost data and ahead of the Federal Open Market Committee's decision on rate
MT NewswiresApr 30 11:59 ET
Jefferies Adjusts Eli Lilly and Co.'s Price Target to $915 From $895, Keeps Buy Rating
Eli Lilly and Co. (LLY) has an average rating of outperform and price targets ranging from $500 to $1,000, according to analysts polled by Capital IQ. Price: 772.42, Change: +35.22, Percent Change: +4
MT NewswiresApr 30 11:54 ET
Invest with SargeOP : I am long the stock. (My edit button disappered)
safri_moomoor : crptor stop
gkoval172 : Thanks for the info, as always
Kevin TraversOP safri_moomoor: Cryptor? Creptor? Crocodile?
No Data
No Data
CanucksOP : May FOMC Preview: Sticky Inflation Likely Forces Fed to Turn More Hawkish